Tuberculosis, BCG Vaccination, and COVID-19: Are They Connected?

Evidence from multiple scientific studies suggests that the Bacillus Calmette-Guerin (BCG) vaccine, widely used worldwide as a preventive measure against tuberculosis, also offers cross-protection against other pathogens. This review aimed to gather data from research that studied the mechanisms involved in the immunological protection induced by the BCG vaccine, which may be important in the control of viral infections, such as COVID-19. Through a literature review, we compiled information about the different BCG strains used worldwide, as well as the responses and protection elicited by them. We commented on the mechanisms of immune response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and we discussed the possibility of cross-protection of different BCG strains on the control of COVID-19. Due to the immunomodulatory properties of BCG, some BCG strains were able to induce an effective cellular immune response and, through epigenetic modifications, activate cells of the innate immune system, such as monocytes, macrophages and natural killer cells, which are crucial for the control of viral infections. Although several vaccines have already been developed and used in an attempt to control the COVID-19 pandemic, some BCG vaccine strains may help stimulate the basal defences against these pathogens and can be used as additional defences in this and future pandemics.

Automated summary

Evidence suggests that the BCG vaccine, used to prevent tuberculosis, may also offer cross-protection against other pathogens. Through a literature review, this article explores the mechanisms of immune response induced by BCG and discusses the potential cross-protection against COVID-19. Some BCG strains are able to stimulate effective cellular immune response and activate innate immune cells, which are crucial for controlling viral infections.